Highest-materiality recent filing
LENSAR shareholders elect three directors, approve say-on-pay and PwC ratification
Elected Class III directors: Ellis (13,430,892), Lindstrom (13,303,843), Link (13,302,526) votes for.
LENSAR appoints Michael A. Rossi as Interim CFO; annual meeting set for Aug 4, 2026
Michael A. Rossi appointed Interim CFO effective May 29, 2026, via consulting agreement with Monomoy Advisors at $375/hour.
Recurring revenue rose 9% YoY to $12.6M (94% of total); total system sales fell to $836K from $2.6M.
LENSAR CFO Thomas R. Staab II to resign effective May 8, 2026
CFO Thomas R. Staab II notified company of resignation on April 10, 2026, effective May 8, 2026.
LENSAR Q4 revenue $16.0M (-4% YoY); recurring revenue up 17% to $12.7M
Net loss narrowed to $1.5M ($0.12/sh) from $18.7M loss a year ago, largely on warrant liability fair-value change.
LENSAR terminates merger with Alcon; retains $10M deposit; FTC intended to challenge deal
Merger agreement terminated effective March 16, 2026; FTC intended to seek injunction.
LENSAR secures $9.2M revolving credit facility from Wells Fargo secured by brokerage account
Revolving, non-purpose margin facility secured by a first-priority lien on a designated brokerage account at Wells Fargo.
LENSAR enters $50M revolving credit facility with Wells Fargo secured by brokerage account
Revolving non-purpose margin credit facility up to $50M, secured by first-priority lien on a designated brokerage account at Wells Fargo.
LENSAR acquisition by Alcon faces FTC second request; closing expected H1 2026
LENSAR and Alcon continue cooperating with FTC on Second Request and review.
LENSAR stockholders elect three Class II directors, ratify PwC as auditor at 2025 annual meeting
Nicholas T. Curtis elected with 14,344,298 votes FOR, 1,101,660 WITHHELD, 2,067,913 broker non-votes.
LENSAR Q3 revenue $14.3M, net loss $3.7M; ALLY installed base grows 77% YoY
Revenue $14.3M, +6% YoY; net loss $3.7M ($0.31/share) vs $1.5M loss in Q3 2024.
LENSAR sets Dec 18 2025 annual meeting, contingent on pending Alcon merger not closing first
Annual meeting scheduled for December 18, 2025; record date October 24, 2025.
LENSAR Q2 revenue up 10% to $13.9M; ALLY placements surge; Alcon merger on track
Q2 2025 revenue $13.9M (+10% YoY); procedure volume up 23% to 52,100.
LENSAR stockholders approve merger with Alcon Research
15,983,846 votes for the merger, 26,033 against, 5,113 abstentions; 80.69% quorum.
FTC issues Second Request for LENSAR-Alcon merger, extending HSR waiting period
LENSAR and Alcon each received a Second Request from the FTC regarding the pending merger.
LENSAR Q1 revenue $14.2M (+34% YoY); net loss $27.3M on warrant liability
Total revenue $14.2M vs $10.6M in Q1 2024, driven by system sales and 33% procedure volume growth.
LENSAR Q1 revenue up 34% to $14.2M; net loss $27.3M on warrant liability adjustment
Total revenue $14.2M (+34% YoY); recurring revenue $11.5M (81% of total).
Alcon acquires LENSAR for $14.00/share cash plus CVR up to $2.75, total ~$430M
Per-share consideration: $14.00 cash plus contingent value right (CVR) of up to $2.75 if 614,000 cumulative procedures achieved by Dec 31, 2027.
LENSAR Q4 revenue $16.7M (+38% YoY); positive Adj. EBITDA; ALLY placements surge
Q4 revenue $16.7M, up 38% YoY; full-year revenue +27% YoY to ~$54M (implied).
LENSAR Q3 revenue $13.5M (+38% YoY); 24 ALLY placements; adj. EBITDA positive
Total revenue $13.5M, up 38% YoY; procedure volume +29% worldwide.
LENSAR Reports Q2 2024 Results with 17 ALLY Placements and Terminates Oertli Development Agreement
Q2 2024 revenue $12.6M, up 5% YoY; net loss $9.0M vs $8.8M loss in Q2 2023.
LENSAR stockholders elect O'Farrell and Winer as Class I directors, ratify PwC
Elizabeth G. O'Farrell received 13,650,553 votes FOR, 1,705,445 WITHHELD; Gary M. Winer received 13,322,586 FOR, 2,033,412 WITHHELD.
LENSAR Q1 revenue $10.6M (+28% YoY); net loss narrows to $2.2M
Total revenue $10.6M for Q1 2024, up 28% YoY; net loss $2.2M ($0.19 per share) vs $4.3M ($0.40) loss in Q1 2023.
LENSAR grants performance-based equity awards to officers with $75M/$100M revenue targets
CEO Nicholas T. Curtis receives 71,400 RSUs and 71,400 PSUs; other officers also receive awards.
LENSAR Q4 revenue up 18% to $12.1M; 44 ALLY systems placed in 2023, beating 30 target
Q4 2023 revenue $12.1M (+18% YoY); full-year revenue up 19% from 2022.
LENSAR adopts inducement plan (100k shares), raises three execs' base salaries 4%
Board approved 2024 Employment Inducement Incentive Award Plan, reserving 100,000 shares for new-hire inducement grants.
LENSAR board approves 2023 annual cash bonuses at 103% of target for three named officers
Bonuses approved Jan 31, 2024 for CEO Nick Curtis, Alan Connaughton, and Thomas Staab at 103% of target.
LENSAR Q3 revenue $9.8M (+26% YoY); net income $2.6M vs -$4.0M loss; ALLY installed base 39
Revenue $9.8M, +26% YoY ($7.7M); U.S. procedure volume +16% YoY.
LENSAR director John P. McLaughlin to retire effective Oct 31, 2023
John P. McLaughlin notified the Board of his retirement on October 9, 2023.
LENSAR Q2 revenue up 49% YoY to $12M; ALLY installed base grows to 28 systems
Total revenue $12.0 million, +49% YoY; net loss $8.8M ($0.81/share) vs $6.8M loss prior year.
LENSAR shareholders approve issuance of shares to North Run Capital affiliate in special meeting
Proposal to issue shares upon conversion of Series A preferred stock and exercise of warrants to affiliate of North Run Capital, LP approved.
LENSAR stockholders elect two Class III directors, ratify PwC, expand board to nine
William J. Link and Richard L. Lindstrom elected as Class III directors with 5,883,023 and 5,910,865 votes for, respectively.
Gross proceeds of $20M from sale of 20,000 Series A Convertible Preferred Shares (stated value $1,000) and warrants to NR-GRI Partners, an affiliate of North Run Capital.
Revenue $8.3M, down 12% YoY; net loss $4.3M ($0.40/sh) vs $6.7M loss in Q1 2022.
LENSAR enters $20M securities purchase agreement with North Run Capital affiliate
Sold 20,000 Series A Convertible Preferred Shares at $1,000 stated value each for $20M gross proceeds.
LENSAR Q4 2022 revenue $10.2M (-9% YoY); net loss narrows to $2.5M from $3.9M
Q4 2022 total revenue $10.2M, down 9% from $11.2M in Q4 2021 due to lower South Korea procedure revenue.
LENSAR reports Q4 rev ~$10.2M (-9% YoY), FY rev ~$35.4M; ALLY System installations at 10
Q4 2022 revenue approximately $10.2M, down from $11.2M in Q4 2021; up 32% sequentially from Q3 2022.
LENSAR approves 2022 bonuses at 90% of target, 4.5% raise, equity grants for officers
Board approved 2022 annual cash bonuses at 90% of target for CEO Curtis, CFO Connaughton, COO Staab.
LENSAR Q3 2022 revenue down 6% to $7.7M; net loss narrows to $4.0M; launches ALLY system
Revenue $7.7M, down 6% YoY; U.S. procedure volume up 9%, offset by South Korean reimbursement challenges.
LENSAR applies for CE Mark certification of ALLY System in European Union
Application for CE Mark certification of the ALLY Adaptive Cataract Treatment System submitted.
LENSAR announces first commercial ALLY System cases; Dr. Weinstock performs 15 surgeries
First commercial cases performed with ALLY System by Dr. Robert Weinstock at The Eye Institute of West Florida.
LENSAR Q2 revenue $8.0M (+1% YoY), net loss ($6.8M); FDA OK for ALLY system
Net loss of ($6.8M) or ($0.67)/share vs. ($4.4M) or ($0.47)/share in Q2 2021.
LENSAR holds commercial launch meeting for ALLY System after FDA clearance
LENSAR (LNSR) held commercial launch meeting week of June 27, 2022 for ALLY Adaptive Cataract Treatment System.
LENSAR receives FDA 510(k) clearance for ALLY Adaptive Cataract Treatment System
FDA 510(k) clearance received on June 9, 2022 for next-generation ALLY system.
LENSAR shareholders elect Curtis and Weisner as Class II directors, ratify PwC as auditor
Nicholas T. Curtis received 5,962,722 votes FOR, Aimee S. Weisner 5,957,948 FOR.
LENSAR Q1 2022 revenue $9.3M (+33% YoY); net loss $6.7M; ALLY 510(k) under FDA review
Total revenue $9.3M, up 33% from $7.0M in Q1 2021; 89% from recurring sources.
LENSAR Q4 2021 revenue $11.2M (+35% YoY); full-year revenue up 31% to $34.2M; net loss narrows
Q4 revenue $11.2M vs $8.3M YoY; full-year revenue $34.2M (+31% vs 2020).
FDA accepts LENSAR's 510(k) for ALLY Adaptive Cataract Treatment System for substantive review
510(k) submission for next-gen ALLY system accepted for substantive review by FDA.
LENSAR appoints Kendra W. Wong as Principal Accounting Officer; grants equity awards to executives
Kendra W. Wong appointed Principal Accounting Officer on Jan 11, 2022; base salary raised to $225,000, target bonus 30%.
LENSAR Q3 2021 revenue $8.3M (+16% YoY), net loss widens to $6.2M
Revenue $8.3M, up 16% YoY; procedure volumes grew 23% over Q3 2020.
On May 25, 2026, the Board of Directors (the “Board”) of LENSAR, Inc. (the “Company”) appointed Michael A. Rossi to serve as the Company’s Interim Chief Financial Officer and principal financial officer, effective as of May 29, 2026.
On October 9, 2023, John P. McLaughlin notified the Board of Directors (the “Board”) of LENSAR, Inc. (the “Company”) of his intent to retire from the Board, effective October 31, 2023.
Also on May 12, 2023, in connection with the Offering and pursuant to the Purchase Agreement and subject to the closing of the Offering, the Board appointed each of Thomas B. Ellis and Todd B. Hammer to the Board effective immediately following the 2023 Annual Meeting of Stockholders.
Also on May 12, 2023, in connection with the Offering and pursuant to the Purchase Agreement and subject to the closing of the Offering, the Board appointed each of Thomas B. Ellis and Todd B. Hammer to the Board effective immediately following the 2023 Annual Meeting of Stockholders.
On January 11, 2022, the Board of Directors (the “Board”) of LENSAR, Inc. (the “Company”) appointed Kendra W. Wong, previously the Company’s Director of Financial Operations, to serve as the Company’s Principal Accounting Officer, effective immediately.
Max materiality 0.95 · Median 0.65 · Most common event earnings